AbbVie Raises 2026 Forecast and Dividend as Skyrizi, Rinvoq Lift Sales 10.3%
AbbVie raised its full-year profit forecast and lifted its dividend for 2027 after third-quarter sales climbed 10.3% on strength in its two big immunology drugs, the company said in its earnings release on Friday.
Net revenue rose to $17.404 billion in the quarter ended Sept. 30, up 10.3% on a reported basis and 10.5% at constant currency, according to the release filed with an 8-K. Diluted earnings per share were $2.37 under generally accepted accounting principles, and adjusted diluted EPS was $3.82. AbbVie said both figures more than doubled from a year earlier. The results include a $0.11-a-share hit from acquired research and milestone expense.
Skyrizi and Rinvoq carry the quarter
The immunology portfolio produced $9.165 billion in revenue, up 16.3%. Skyrizi sales rose 22.7% to $5.776 billion and Rinvoq brought in $2.706 billion, up 23.9%. Humira, the former blockbuster now facing biosimilar competition, generated $683 million.
Neuroscience was the fastest-growing segment, with revenue up 19.4% to $3.389 billion. Vraylar sales were $1.068 billion, therapeutic Botox brought in $1.080 billion, and the migraine drugs Ubrelvy and Qulipta combined for $847 million. Vyalev, the Parkinson's treatment, added $286 million.
Oncology revenue edged up 0.8% to $1.696 billion, led by Venclexta at $803 million and Imbruvica at $522 million. The aesthetics business was the weak spot, slipping 1.4% to $1.176 billion as Botox Cosmetic sales came in at $669 million and Juvederm at $222 million.
Guidance and dividend
AbbVie raised its 2026 adjusted diluted EPS forecast to $13.95 to $13.99, up from $13.76 to $13.96. The new range absorbs a $0.69-a-share charge for acquired research and milestones booked through the third quarter.
The company also announced a 5.2% dividend increase that starts with the payment due in February 2027.
"Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend," Chairman and CEO Robert A. Michael said in the release. He also pointed to the completed acquisition of Apogee Therapeutics, which AbbVie said deepens its immunology pipeline.
Why it matters
AbbVie has spent several years replacing Humira's lost sales. With Skyrizi and Rinvoq now generating $8.482 billion a quarter between them, the two newer drugs are carrying the company's growth, while the aesthetics unit remains a drag.
By the numbers
- $17.404 billion: third-quarter net revenue, up 10.3%
- $3.82: adjusted diluted EPS
- $5.776 billion: Skyrizi sales, up 22.7%
- $2.706 billion: Rinvoq sales, up 23.9%
- $13.95 to $13.99: new 2026 adjusted EPS guidance
- 5.2%: dividend increase for 2027
Sources
- AbbVie Form 8-K with third-quarter 2026 earnings release (Exhibit 99.1), filed Oct. 30, 2026 (accession 0001551152-26-000033)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.